HHS 允许持证药房与医生临时配制六种实验性肽类,FDA 科学家提出异议
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
HHS 发布政策,允许持证药房和医生临时配制六种实验性肽类,其中包括 BPC-157 和 TB-500,联邦层面暂不对此执法。FDA 职业科学家对此表示反对,认为目前缺乏证据表明这些物质安全或有效。报道由 STAT 的 Margaret Manto 撰写,称此举是对当前肽类热潮的监管助推。
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
I have a cold again. Cure it, science.
HHS opens peptide floodgates, despite concerns from FDA scientists
The Trump administration is giving the peptide craze a regulatory boost. HHS issued a policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides, including the popular injury-recovery duo BPC-157 and TB-500, without fear of federal enforcement, STAT’s Margaret Manto writes. This comes despite objections from FDA career scientists who say there’s scant evidence the substances are safe or effective.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com